Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 19/20 | 0.46 |
| ▸ | CTSV | O60911 | 18/20 | 0.46 |
| ▸ | CTSS | P25774 | 18/20 | 0.46 |
| ▸ | CTSK | P43235 | 14/20 | 0.46 |
| ▸ | CTSB | P07858 | 11/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20630582 | 1.00 | CTSL (0.46) | CTSLCTSVCTSSCTSKCTSB | |
| SCHEMBL21895954 | 0.90 | CTSL (0.39) | CTSLCTSVCTSSCTSKCTSB | |
| SCHEMBL28366266 | 0.90 | CTSL (0.39) | CTSLCTSVCTSSCTSKCTSB | |
| SCHEMBL7074223 | 0.88 | ACE (0.47) | CTSLCTSSCTSKCTSB | |
| SCHEMBL7074221 | 0.88 | ACE (0.47) | CTSLCTSSCTSKCTSB | |
| SCHEMBL15083401 | 0.88 | CTSB (0.45) | CTSLCTSSCTSKCTSB | |
| SCHEMBL16288443 | 0.88 | CTSB (0.45) | CTSLCTSSCTSKCTSB | |
| SCHEMBL22686106 | 0.84 | CTSS (0.48) | CTSLCTSSCTSKCTSB | |
| SCHEMBL21837702 | 0.84 | ALDH1A1 (0.41) | — | |
| SCHEMBL21837699 | 0.84 | ALDH1A1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110869544-B | Cyclic peptide compound having high membrane permeability and library comprising same | 中外制药株式会社 | 2024-03-08 | — | — | CN | disclosed |
| US-20200131669-A1 | CYCLIC PEPTIDE COMPOUND HAVING HIGH MEMBRANE PERMEABILITY, AND LIBRARY CONTAINING SAME | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2020-04-30 | — | — | US | disclosed |
| EP-3636807-A1 | CYCLIC PEPTIDE COMPOUND HAVING HIGH MEMBRANE PERMEABILITY, AND LIBRARY CONTAINING SAME | Chugai Seiyaku Kabushiki Kaisha (JP) | 2020-04-15 | — | — | EP | disclosed |
| EP-3424941-A1 | PRODUCTION METHOD FOR NONCYCLIC PEPTIDE-NUCLEIC ACID COMPLEX HAVING, AT N-TERMINAL, AMINO ACID WITH THIOL GROUP NEAR AMINO GROUP, LIBRARY THEREOF, AND CYCLIC PEPTIDE-NUCLEIC ACID COMPLEX LIBRARY DERIVED FROM SAME | Chugai Seiyaku Kabushiki Kaisha (JP) | 2019-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131669-A1 | CYCLIC PEPTIDE COMPOUND HAVING HIGH MEMBRANE PERMEABILITY, AND LIBRARY CONTAINING SAME | VIP, SLC7A1, TRPV1 | CTSL 974/4885CTSV 1461/4885CTSS 2046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.